Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.76 USD | -2.76% | -6.88% | +38.58% |
May. 21 | HC Wainwright Adjusts Inhibikase Therapeutics Price Target to $23 From $27, Maintains Buy Rating | MT |
May. 16 | Transcript : Inhibikase Therapeutics, Inc., Q1 2024 Earnings Call, May 16, 2024 |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 13.02M |
---|---|---|---|---|---|
Net income 2024 * | -18M | Net income 2025 * | -26M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.94
x | P/E ratio 2025 * |
-1.33
x | Employees | 9 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 77.32% |
Latest transcript on Inhibikase Therapeutics, Inc.
1 day | -2.76% | ||
1 week | -6.88% | ||
Current month | +19.73% | ||
1 month | +2.92% | ||
3 months | -20.72% | ||
6 months | +95.56% | ||
Current year | +38.58% |
Managers | Title | Age | Since |
---|---|---|---|
Milton Werner
FOU | Founder | 61 | 08-08-31 |
C. Warren Olanow
CTO | Chief Tech/Sci/R&D Officer | - | 21-01-03 |
Dan Williams
AUD | Comptroller/Controller/Auditor | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Dennis Berman
BRD | Director/Board Member | 73 | 19-08-31 |
Paul Grint
BRD | Director/Board Member | 66 | 20-12-21 |
Milton Werner
FOU | Founder | 61 | 08-08-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 1.76 | -2.76% | 20,639 |
24-05-24 | 1.81 | -1.09% | 33,059 |
24-05-23 | 1.83 | -3.17% | 28,337 |
24-05-22 | 1.89 | 0.00% | 29,703 |
24-05-21 | 1.89 | +1.61% | 36,882 |
Delayed Quote Nasdaq, May 28, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+38.58% | 13.02M | |
+54.05% | 63.85B | |
-2.02% | 41.83B | |
+40.01% | 40.47B | |
-10.22% | 27.17B | |
+13.42% | 26.52B | |
-21.60% | 18.69B | |
+2.89% | 12.73B | |
+22.40% | 12.11B | |
+27.49% | 12.07B |
- Stock Market
- Equities
- IKT Stock